Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.
Profitability
This table compares Tactile Systems Technology and Delcath Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tactile Systems Technology | 5.91% | 9.70% | 7.53% |
| Delcath Systems | 0.62% | 0.51% | 0.46% |
Analyst Ratings
This is a summary of recent ratings and price targets for Tactile Systems Technology and Delcath Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tactile Systems Technology | 0 | 2 | 4 | 1 | 2.86 |
| Delcath Systems | 1 | 1 | 5 | 0 | 2.57 |
Insider and Institutional Ownership
83.4% of Tactile Systems Technology shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 2.1% of Tactile Systems Technology shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Tactile Systems Technology and Delcath Systems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tactile Systems Technology | $329.52 million | 2.10 | $19.09 million | $0.88 | 34.86 |
| Delcath Systems | $85.23 million | 5.48 | $2.70 million | $0.01 | 1,352.00 |
Tactile Systems Technology has higher revenue and earnings than Delcath Systems. Tactile Systems Technology is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Tactile Systems Technology has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.
Summary
Tactile Systems Technology beats Delcath Systems on 10 of the 15 factors compared between the two stocks.
About Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company also provides Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.
